MA41375A - Anticorps igg bispécifiques et leurs procédés de préparation - Google Patents

Anticorps igg bispécifiques et leurs procédés de préparation

Info

Publication number
MA41375A
MA41375A MA041375A MA41375A MA41375A MA 41375 A MA41375 A MA 41375A MA 041375 A MA041375 A MA 041375A MA 41375 A MA41375 A MA 41375A MA 41375 A MA41375 A MA 41375A
Authority
MA
Morocco
Prior art keywords
igg antibodies
preparation processes
bispecific igg
bispecific
processes
Prior art date
Application number
MA041375A
Other languages
English (en)
Inventor
Hector Aldaz
Shane Atwell
Stephen J Demarest
Karen J Froning
Brian Arthur Kuhlman
Andrew Philip Leaver-Fay
Original Assignee
Lilly Co Eli
Univ North Carolina Chapel Hill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli, Univ North Carolina Chapel Hill filed Critical Lilly Co Eli
Publication of MA41375A publication Critical patent/MA41375A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
MA041375A 2015-01-22 2016-01-20 Anticorps igg bispécifiques et leurs procédés de préparation MA41375A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562106494P 2015-01-22 2015-01-22

Publications (1)

Publication Number Publication Date
MA41375A true MA41375A (fr) 2017-11-28

Family

ID=55358122

Family Applications (1)

Application Number Title Priority Date Filing Date
MA041375A MA41375A (fr) 2015-01-22 2016-01-20 Anticorps igg bispécifiques et leurs procédés de préparation

Country Status (4)

Country Link
US (2) US10774156B2 (fr)
EP (1) EP3247721A1 (fr)
MA (1) MA41375A (fr)
WO (1) WO2016118742A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2970435B1 (fr) * 2013-03-15 2020-08-12 Eli Lilly and Company Procédés de production de fab et d'anticorps bispécifiques
US11820828B2 (en) 2016-12-22 2023-11-21 Eli Lilly And Company Methods for producing fabs and IgG bispecific antibodies
CN110382529B (zh) 2017-03-02 2024-03-08 诺华股份有限公司 工程化的异源二聚体蛋白质
CN110869394A (zh) 2017-06-16 2020-03-06 伊莱利利公司 工程改造的抗体化合物及其缀合物
MX2020002070A (es) 2017-08-22 2020-03-24 Sanabio Llc Receptores solubles de interferon y usos de los mismos.
WO2019199916A1 (fr) * 2018-04-13 2019-10-17 Eli Lilly And Company Anticorps trispécifiques à base de fab
TWI722535B (zh) 2018-08-21 2021-03-21 美商美國禮來大藥廠 測定蛋白質或肽濃度的方法及其用途
EP3927383A4 (fr) * 2019-02-18 2022-11-09 Lankenau Institute for Medical Research Matériaux de fermeture de plaie réduisant la cicatrice
MX2021013646A (es) * 2019-05-09 2022-01-31 Merus Nv Dominios variantes para las proteínas multimerizantes y su separación.
WO2021046072A1 (fr) 2019-09-06 2021-03-11 Eli Lilly And Company Protéines comprenant des domaines constants de récepteur de lymphocytes t
WO2021194839A1 (fr) 2020-03-25 2021-09-30 Eli Lilly And Company Protéines de liaison multispécifiques et leurs procédés de développement
CN114106192A (zh) * 2021-12-20 2022-03-01 广州爱思迈生物医药科技有限公司 双特异性抗体及其应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US573168A (en) 1896-12-15 silberman
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7754209B2 (en) * 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
CN101035808B (zh) 2004-08-05 2012-10-31 健泰科生物技术公司 人源化抗c-met拮抗剂
ES2592271T3 (es) 2005-03-31 2016-11-29 Chugai Seiyaku Kabushiki Kaisha Métodos de producción de polipéptidos mediante la regulación de la asociación de los polipéptidos
GEP20135917B (en) 2006-03-17 2013-09-10 Biogen Idec Inc Stabilized polypeptide compositions
JP2009541275A (ja) 2006-06-22 2009-11-26 ノボ・ノルデイスク・エー／エス 二重特異性抗体の生産
NZ614857A (en) 2007-03-29 2015-04-24 Genmab As Bispecific antibodies and methods for production thereof
US8802089B2 (en) * 2008-01-03 2014-08-12 Genmab A/S Monoclonal antibodies against CD32B
ES2774337T3 (es) 2008-01-07 2020-07-20 Amgen Inc Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática
WO2011028952A1 (fr) 2009-09-02 2011-03-10 Xencor, Inc. Compositions et procédés pour une co-liaison bivalente et monovalente simultanée d'antigènes
DK2580243T3 (da) * 2010-06-09 2020-01-13 Genmab As Antibodies against human cd38
AU2011325833C1 (en) 2010-11-05 2017-07-13 Zymeworks Bc Inc. Stable heterodimeric antibody design with mutations in the Fc domain
NZ608724A (en) 2011-03-25 2015-12-24 Glenmark Pharmaceuticals Sa Hetero-dimeric immunoglobulins
EP2748197A2 (fr) 2011-08-26 2014-07-02 Merrimack Pharmaceuticals, Inc. Anticorps bispécifiques à fc en tandem
KR102052774B1 (ko) 2011-11-04 2019-12-04 자임워크스 인코포레이티드 Ｆｃ 도메인 내의 돌연변이를 갖는 안정한 이종이합체 항체 설계
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
US9914785B2 (en) 2012-11-28 2018-03-13 Zymeworks Inc. Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
EP2970435B1 (fr) 2013-03-15 2020-08-12 Eli Lilly and Company Procédés de production de fab et d'anticorps bispécifiques
TW201517916A (zh) 2013-03-15 2015-05-16 Lilly Co Eli Ｖｅｇｆｒ１抗體之治療用途
WO2014154254A1 (fr) 2013-03-26 2014-10-02 Nokia Solutions And Networks Oy Méthode et appareil
WO2016016299A1 (fr) * 2014-07-29 2016-02-04 F. Hoffmann-La Roche Ag Anticorps multispécifiques
EP3356420B1 (fr) * 2015-10-02 2023-11-01 F. Hoffmann-La Roche AG Anticorps multispécifiques
US11820828B2 (en) * 2016-12-22 2023-11-21 Eli Lilly And Company Methods for producing fabs and IgG bispecific antibodies
CN110382529B (zh) * 2017-03-02 2024-03-08 诺华股份有限公司 工程化的异源二聚体蛋白质
AR112341A1 (es) * 2017-08-02 2019-10-16 Lilly Co Eli ANTICUERPOS BIESPECÍFICOS ANTI-TNF- / ANTI-IL-23 DE IgG
WO2019199916A1 (fr) * 2018-04-13 2019-10-17 Eli Lilly And Company Anticorps trispécifiques à base de fab

Also Published As

Publication number Publication date
US20180009908A1 (en) 2018-01-11
EP3247721A1 (fr) 2017-11-29
US10774156B2 (en) 2020-09-15
US20210054103A1 (en) 2021-02-25
WO2016118742A1 (fr) 2016-07-28

Similar Documents

Publication Publication Date Title
MA41375A (fr) Anticorps igg bispécifiques et leurs procédés de préparation
MA43389A (fr) Anticorps anti-ox40 et leurs procédés d'utilisation
MA42935A (fr) Anticorps bispécifiques anti-cd3 optimisés et leurs utilisations
MA43955A (fr) Anticorps anti-bcma et anti-cd3 bispécifiques de format bite
MA50949A (fr) Anticorps anti-ctla-4 et leurs procédés d'utilisation
MA46770A (fr) Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation
MA49537A (fr) Anticorps anti-lag3 et leurs utilisations
MA53355A (fr) Anticorps anti-ctla-4 et leurs procédés d'utilisation
MA46525A (fr) Anticorps anti-lag-3 et compositions
MA49687A (fr) Anticorps anti-ctla-4 et leurs utilisations
MA53184A (fr) Anticorps anti-ox40 et leurs utilisations
MA42626A (fr) Nouveaux anticorps anti-pd-1
MA46529A (fr) Anticorps anti-lag-3 et leurs procédés d'utilisation
MA42447A (fr) Anticorps anti-pd-1, anticorps anti-pd-1 activables, et leurs procédés d'utilisation
MA46708A (fr) Anticorps anti-pd1 et leurs utilisations
DK3368572T3 (da) Anti-pd-1-antistoffer og -sammensætninger
DK3515487T3 (da) Bispecifikke anti-MUC16-CD3-antistoffer og anti-MUC16-lægemiddelkonjugater
MA44659A (fr) Anticorps anti-tim-3 et compositions
MA45235A (fr) Anticorps anti-c5 et leurs utilisations
MA53297A (fr) Anticorps anti-icos
MA42043A (fr) Anticorps anti-ox40 et procédés d'utilisation de ceux-ci
MA45004A (fr) Anticorps spécifiques anti-wt1-hla
SG11201705252UA (en) Anti-pd-1 monoclonal antibodies and obtaining method thereof
MA50505A (fr) Anticorps 2 + 1 bispécifiques (contorsbodies)
MA43658A (fr) Anticorps anti-ror1, anticorps bispécifiques ror1 x cd3, et leurs procédés d'utilisation